

Ibrahim El-Battrawy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2461066/publications.pdf>

Version: 2024-02-01

186
papers

2,953
citations

212478

28
h-index

263392

45
g-index

191
all docs

191
docs citations

191
times ranked

2999
citing authors

#	ARTICLE	IF	CITATIONS
1	Ethnic comparison in takotsubo syndrome: novel insights from the International Takotsubo Registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 186-196.	1.5	8
2	Preclinical short QT syndrome models: studying the phenotype and drug-screening. <i>Europace</i> , 2022, 24, 481-493.	0.7	10
3	Phrenic Nerve Injury During Cryoballoon-Based Pulmonary Vein Isolation: Results of the Worldwide YETI Registry. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, CIRCEP121010516.	2.1	39
4	Impact of sacubitril/valsartan on cardiac arrest event rate. Letter regarding the article "Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-AMI): design and baseline characteristics". <i>European Journal of Heart Failure</i> , 2022, 24, 1324-1324.	2.9	3
5	Takotsubo Syndrome: Translational Implications and Pathomechanisms. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1951.	1.8	23
6	Real life experience with the wearable cardioverter-defibrillator in an international multicenter Registry. <i>Scientific Reports</i> , 2022, 12, 3203.	1.6	5
7	Regulation of Ion Channel Function in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes by Cancer Cell Secretion Through DNA Methylation. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 839104.	1.1	3
8	Pooled Analysis of Complications with Transvenous ICD Compared to Subcutaneous ICD in Patients with Catecholaminergic Polymorphic Ventricular Arrhythmia. <i>Journal of Personalized Medicine</i> , 2022, 12, 536.	1.1	6
9	Glucose Counteracts Isoprenaline Effects on Ion Channel Functions in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 76.	0.8	0
10	Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 535-544.	1.0	9
11	Cardiac disease and prognosis associated with ventricular tachyarrhythmias in young adults and adults. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 136.	0.7	0
12	A Case Series of Concomitant Cardiac Electrical Disease among Takotsubo Syndrome Patients and Literature Review. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 79.	0.8	1
13	Thalassaemia is paradoxically associated with a reduced risk of in-hospital complications and mortality in COVID-19: Data from an international registry. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 2520-2528.	1.6	6
14	Brugada Syndrome: Different Experimental Models and the Role of Human Cardiomyocytes From Induced Pluripotent Stem Cells. <i>Journal of the American Heart Association</i> , 2022, 11, e024410.	1.6	10
15	Antiarrhythmic Effects of Vernakalant in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with Short QT Syndrome Type 1. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 112.	0.8	2
16	Lipopolysaccharide Modifies Sodium Current Kinetics through ROS and PKC Signalling in Induced Pluripotent Stem-Derived Cardiomyocytes from Brugada Syndrome Patient. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 119.	0.8	2
17	Gender Differences in Takotsubo Syndrome. <i>Journal of the American College of Cardiology</i> , 2022, 79, 2085-2093.	1.2	33
18	Kidney Failure among Patients with Takotsubo Syndrome or Myocardial Infarction: A Retrospective Analysis. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 186.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry. Internal and Emergency Medicine, 2021, 16, 957-966.	1.0	22
20	Abnormal thyroid function is common in takotsubo syndrome and depends on two distinct mechanisms: results of a multicentre observational study. Journal of Internal Medicine, 2021, 289, 675-687.	2.7	42
21	Alpha 1-adrenoceptor signalling contributes to toxic effects of catecholamine on electrical properties in cardiomyocytes. Europace, 2021, 23, 1137-1148.	0.7	11
22	Prognostic Impact of Percutaneous Coronary Intervention of Chronic Total Occlusion in Acute and Periprocedural Myocardial Infarction. Journal of Clinical Medicine, 2021, 10, 258.	1.0	9
23	Different genotypes of Brugada syndrome may present different clinical phenotypes: electrophysiology from bench to bedside. European Heart Journal, 2021, 42, 1270-1272.	1.0	10
24	Prognostic impact of acute pulmonary triggers in patients with takotsubo syndrome: new insights from the International Takotsubo Registry. ESC Heart Failure, 2021, 8, 1924-1932.	1.4	8
25	The current evidence of Takotsubo syndrome. Future Cardiology, 2021, 17, 1293-1295.	0.5	2
26	Electrical storm reveals worse prognosis compared to myocardial infarction complicated by ventricular tachyarrhythmias in ICD recipients. Heart and Vessels, 2021, 36, 1701-1711.	0.5	3
27	Incidence and Clinical Impact of Right Ventricular Involvement (Biventricular Ballooning) in Takotsubo Syndrome. Chest, 2021, 160, 1433-1441.	0.4	16
28	Does there exist an obesity paradox in COVID-19? Insights of the international HOPE-COVID-19-registry. Obesity Research and Clinical Practice, 2021, 15, 275-280.	0.8	20
29	Effects of Antiarrhythmic Drugs on hERG Gating in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1. Frontiers in Pharmacology, 2021, 12, 675003.	1.6	5
30	Functional characterization of drug responses in induced pluripotent stem cell-derived cardiomyocytes from a short QT syndrome type 5 patient. Europace, 2021, 23, .	0.7	0
31	β1-adrenoceptors and takotsubo syndrome: pathophysiologic connotations” Authors’™ reply. Europace, 2021, 23, 1152-1152.	0.7	0
32	TRPV1 activation and internalization is part of the LPS-induced inflammation in human iPSC-derived cardiomyocytes. Scientific Reports, 2021, 11, 14689.	1.6	13
33	COVID-19 and the impact of arterial hypertension” An analysis of the international HOPE COVID-19 Registry (Italy-Spain-Germany). European Journal of Clinical Investigation, 2021, 51, e13582.	1.7	14
34	Effect of Anemia on the Prognosis of Patients with Ventricular Tachyarrhythmias. American Journal of Cardiology, 2021, 154, 54-62.	0.7	0
35	Comparison of the prognosis and outcome of heart failure with reduced ejection fraction patients treated with sacubitril/valsartan according to age. Future Cardiology, 2021, 17, 1131-1142.	0.5	9
36	Prognostic factors at admission on patients with cancer and COVID-19: Analysis of HOPE registry data. Medicina Clínica, 2021, 157, 318-324.	0.3	4

#	ARTICLE	IF	CITATIONS
37	Prognostic factors at admission on patients with cancer and COVID-19: Analysis of HOPE registry data. <i>Medicina Clínica (English Edition)</i> , 2021, 157, 318-324.	0.1	4
38	Sepsis of Patients Infected by SARS-CoV-2: Real-World Experience From the International HOPE-COVID-19-Registry and Validation of HOPE Sepsis Score. <i>Frontiers in Medicine</i> , 2021, 8, 728102.	1.2	14
39	Clinical Outcomes in Patients with Ischemic versus Non-Ischemic Cardiomyopathy after Angiotensin-Neprilysin Inhibition Therapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 4989.	1.0	10
40	Abnormal Cardiac Repolarization in Thyroid Diseases: Results of an Observational Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 738517.	1.1	2
41	Dopamine D1/D5 Receptor Signaling Is Involved in Arrhythmogenesis in the Setting of Takotsubo Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 777463.	1.1	4
42	Deciphering the pathogenic role of a variant with uncertain significance for short QT and Brugada syndromes using gene-edited human-induced pluripotent stem cell-derived cardiomyocytes and preclinical drug screening. <i>Clinical and Translational Medicine</i> , 2021, 11, e646.	1.7	11
43	230 Antiplatelet therapy and outcome in COVID-19. Results from a multi-centre international prospective registry (HOPE-COVID). <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
44	123 Prophylactic anticoagulation and aspirin therapy for hospitalized patients with COVID-19: a propensity score-matched analysis of the hope-COVID-19 registry. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
45	Sex-differences in short QT syndrome: A systematic literature review and pooled analysis. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1335-1338.	0.8	12
46	Prevalence, management, and outcome of adverse rhythm disorders in takotsubo syndrome: insights from the international multicenter GEIST registry. <i>Heart Failure Reviews</i> , 2020, 25, 505-511.	1.7	35
47	Improved Outcome of Cardiogenic Shock Triggered by Takotsubo Syndrome Compared With Myocardial Infarction. <i>Canadian Journal of Cardiology</i> , 2020, 36, 860-867.	0.8	7
48	Impact of aspirin on takotsubo syndrome: a propensity score-based analysis of the InterTAK Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 330-337.	2.9	24
49	Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 279-287.	1.1	34
50	Clinical Profile and Long-Term Follow-Up of Children with Brugada Syndrome. <i>Pediatric Cardiology</i> , 2020, 41, 290-296.	0.6	3
51	Arrhythmic events in Brugada syndrome patients induced by fever. <i>Annals of Noninvasive Electrocardiology</i> , 2020, 25, e12723.	0.5	14
52	Association Between Mortality and Left Ventricular Ejection Fraction in Patients With Takotsubo Syndrome Versus Acute Coronary Syndrome. <i>In Vivo</i> , 2020, 34, 3639-3648.	0.6	2
53	Incidence, determinants and prognostic relevance of dyspnea at admission in patients with Takotsubo syndrome: results from the international multicenter GEIST registry. <i>Scientific Reports</i> , 2020, 10, 13603.	1.6	20
54	Ionic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1. <i>Frontiers in Pharmacology</i> , 2020, 11, 554422.	1.6	10

#	ARTICLE	IF	CITATIONS
55	Coexistence and outcome of coronary artery disease in Takotsubo syndrome. <i>European Heart Journal</i> , 2020, 41, 3255-3268.	1.0	49
56	The Use of Beta Blockers in Takotsubo Syndrome as Compared to Acute Coronary Syndrome. <i>Frontiers in Pharmacology</i> , 2020, 11, 681.	1.6	6
57	Current evidence of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. <i>Future Cardiology</i> , 2020, 16, 227-236.	0.5	16
58	The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up. <i>Journal of Clinical Medicine</i> , 2020, 9, 893.	1.0	13
59	Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry. <i>Journal of Nephrology</i> , 2020, 33, 737-745.	0.9	81
60	Intronic CRISPR Repair in a Preclinical Model of Noonan Syndrome-associated Cardiomyopathy. <i>Circulation</i> , 2020, 142, 1059-1076.	1.6	43
61	Nucleoside Diphosphate Kinase B Contributes to Arrhythmogenesis in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with Arrhythmogenic Right Ventricular Cardiomyopathy. <i>Journal of Clinical Medicine</i> , 2020, 9, 486.	1.0	15
62	Age-Related Variations in Takotsubo Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1869-1877.	1.2	42
63	Long-Term Follow-Up of Patients with Catecholaminergic Polymorphic Ventricular Arrhythmia. <i>Journal of Clinical Medicine</i> , 2020, 9, 903.	1.0	6
64	Risk factor paradox: No prognostic impact of arterial hypertension and smoking in patients with ventricular tachyarrhythmias. <i>Cardiology Journal</i> , 2020, 27, 715-725.	0.5	2
65	Comparison of the Outcome of Patients Protected by the Wearable Cardioverter Defibrillator (WCD) for ≥ 90 Wear Days versus <math>< 90</math> Wear Days. <i>In Vivo</i> , 2020, 34, 3601-3610.	0.6	4
66	Discriminating factors excluding patients from a catheter-based left atrial appendage closure and an outcome analysis of non-intervened and intervened patients. <i>Archives of Medical Science</i> , 2020, , .	0.4	0
67	Cardiac contractility modulation efficacy: is there a difference between ischemic vs. non-ischemic patients?. <i>European Heart Journal</i> , 2020, 41, .	1.0	1
68	Delta CHA2DS2-VASc score as a predictor of stroke. <i>Europace</i> , 2019, 21, 179-179.	0.7	0
69	Assessment of the German and Italian Stress Cardiomyopathy Score for Risk Stratification for In-hospital Complications in Patients With Takotsubo Syndrome. <i>JAMA Cardiology</i> , 2019, 4, 892.	3.0	60
70	Impact of Antiarrhythmic Drugs on the Outcome of Short QT Syndrome. <i>Frontiers in Pharmacology</i> , 2019, 10, 771.	1.6	18
71	Predictors of thromboembolic events in Takotsubo syndrome. <i>European Journal of Heart Failure</i> , 2019, 21, 1482-1482.	2.9	1
72	The Risk for Sudden Cardiac Death and Effect of Treatment With Sacubitril/Valsartan in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 999.	1.9	10

#	ARTICLE	IF	CITATIONS
73	Takotsubo syndrome and cardiac implantable electronic device therapy. <i>Scientific Reports</i> , 2019, 9, 16559.	1.6	12
74	Neurocardiac Injury in Patients With Subarachnoid Hemorrhage. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2094-2095.	2.3	1
75	Outcomes Associated With Cardiogenic Shock in Takotsubo Syndrome. <i>Circulation</i> , 2019, 139, 413-415.	1.6	75
76	“Mature” resting membrane potentials in hiPSC-CMs: fact or artefact? Authors’ reply. <i>Europace</i> , 2019, 21, 1928-1929.	0.7	1
77	Prediction of short- and long-term mortality in takotsubo syndrome: the InterTAK Prognostic Score. <i>European Journal of Heart Failure</i> , 2019, 21, 1469-1472.	2.9	20
78	Implantable cardioverter-defibrillator in Brugada syndrome: Long-term follow-up. <i>Clinical Cardiology</i> , 2019, 42, 958-965.	0.7	21
79	Interaction between the heart and the brain in transient global amnesia. <i>Journal of Neurology</i> , 2019, 266, 3048-3057.	1.8	13
80	Atrial Fibrillation Is Associated with Increased Mortality in Patients Presenting with Ventricular Tachyarrhythmias. <i>Scientific Reports</i> , 2019, 9, 14291.	1.6	6
81	Impact of Sacubitril/Valsartan on the Long-Term Incidence of Ventricular Arrhythmias in Chronic Heart Failure Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 1582.	1.0	33
82	Genotype-phenotype association in patients with SCN4A mutation. <i>Lancet, The</i> , 2019, 393, 2301.	6.3	1
83	Statin therapy is associated with improved survival in patients with ventricular tachyarrhythmias. <i>Lipids in Health and Disease</i> , 2019, 18, 119.	1.2	6
84	A cellular model of Brugada syndrome with SCN10A variants using human-induced pluripotent stem cell-derived cardiomyocytes. <i>Europace</i> , 2019, 21, 1410-1421.	0.7	33
85	Cardiac arrest in takotsubo syndrome: results from the InterTAK Registry. <i>European Heart Journal</i> , 2019, 40, 2142-2151.	1.0	79
86	Incidence and Clinical Impact of Recurrent Takotsubo Syndrome: Results From the GEIST Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010753.	1.6	74
87	Short- and Long-Term Incidence of Thromboembolic Events in Takotsubo Syndrome as Compared With Acute Coronary Syndrome. <i>Angiology</i> , 2019, 70, 838-843.	0.8	12
88	Gender-based comparison of takotsubo syndrome versus myocardial infarction. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2019, 112, 355-362.	0.2	8
89	Impact of ST-segment elevation on the outcome of Takotsubo syndrome. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 251-258.	0.9	3
90	Letter by El-Batrawy et al Regarding Article, “Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis”. <i>Circulation</i> , 2019, 139, 1344-1345.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Long-term follow-up of implantable cardioverter-defibrillators in Short QT syndrome. <i>Clinical Research in Cardiology</i> , 2019, 108, 1140-1146.	1.5	20
92	Drug Testing in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short <sc>QT</sc> Syndrome Type 1. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 642-651.	2.3	21
93	Serum of patients with acute myocardial infarction prevents inflammation in iPSC-cardiomyocytes. <i>Scientific Reports</i> , 2019, 9, 5651.	1.6	6
94	Impact of Tâ€inversion on the outcome of Takotsubo syndrome as compared to acute coronary syndrome. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13078.	1.7	3
95	Studying Brugada Syndrome With an SCN1B Variants in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 261.	1.8	29
96	Comparable survival in ischemic and nonischemic cardiomyopathy secondary to ventricular tachyarrhythmias and aborted cardiac arrest. <i>Coronary Artery Disease</i> , 2019, 30, 303-311.	0.3	3
97	Prognostic impact of chronic kidney disease and renal replacement therapy in ventricular tachyarrhythmias and aborted cardiac arrest. <i>Clinical Research in Cardiology</i> , 2019, 108, 669-682.	1.5	13
98	Protective effect of acquired long QT syndrome in Takotsubo syndrome. <i>Internal Medicine Journal</i> , 2019, 49, 770-776.	0.5	5
99	Prognostic impact of beta-blocker compared to combined amiodarone therapy secondary to ventricular tachyarrhythmias. <i>International Journal of Cardiology</i> , 2019, 277, 118-124.	0.8	7
100	Male sex increases mortality in ventricular tachyarrhythmias. <i>Internal Medicine Journal</i> , 2019, 49, 711-721.	0.5	3
101	Differences in Short QT Syndrome Subtypes: A Systematic Literature Review and Pooled Analysis. <i>Frontiers in Genetics</i> , 2019, 10, 1312.	1.1	12
102	Optimal duration for dual antiplatelet therapy with COMBO dual therapy stent. <i>Journal of Geriatric Cardiology</i> , 2019, 16, 840-843.	0.2	0
103	Sodium channel blockers in Brugada syndrome. <i>Europace</i> , 2018, 20, f139-f139.	0.7	0
104	Letter by El-Batrawy et al Regarding Article, â€œThe Effects of Public Access Defibrillation on Survival After Out-of-Hospital Cardiac Arrest: A Systematic Review of Observational Studiesâ€• <i>Circulation</i> , 2018, 137, 1646-1647.	1.6	0
105	Prevalence and Prognostic Impact of Diabetes in Takotsubo Syndrome: Insights From the International, Multicenter GEIST Registry. <i>Diabetes Care</i> , 2018, 41, 1084-1088.	4.3	53
106	Estradiol protection against toxic effects of catecholamine on electrical properties in human-induced pluripotent stem cell derived cardiomyocytes. <i>International Journal of Cardiology</i> , 2018, 254, 195-202.	0.8	55
107	Impact of left atrial appendage morphology on thrombus formation after successful left atrial appendage occlusion: Assessment with cardiac-computed-tomography. <i>Scientific Reports</i> , 2018, 8, 1670.	1.6	19
108	Myocardial Dysfunction Following Brain Death. <i>Journal of the American College of Cardiology</i> , 2018, 71, 368.	1.2	3

#	ARTICLE	IF	CITATIONS
109	Feasibility of drugs in Brugada syndrome. <i>Europace</i> , 2018, 20, f137-f137.	0.7	1
110	Risk stratification in Takotsubo syndrome: a role of mitral annular plane systolic excursion. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2018, 111, 231-236.	0.2	3
111	Takotsubo Cardiomyopathy: Another Form of Cardiorenal Syndrome. <i>Angiology</i> , 2018, 69, 130-135.	0.8	5
112	Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 52.	0.7	20
113	Long term outcome of patients suffering from cancer and Takotsubo syndrome or myocardial infarction. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2018, 111, 473-481.	0.2	8
114	Long-term results of combined cardiac contractility modulation and subcutaneous defibrillator therapy in patients with heart failure and reduced ejection fraction. <i>Clinical Cardiology</i> , 2018, 41, 518-524.	0.7	15
115	Modeling Short QT Syndrome Using Human-induced Pluripotent Stem Cell-derived Cardiomyocytes. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	88
116	Electrical dysfunctions in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with an arrhythmogenic right ventricular cardiomyopathy. <i>Europace</i> , 2018, 20, f46-f56.	0.7	50
117	Ion Channel Dysfunctions in Dilated Cardiomyopathy in Limb-Girdle Muscular Dystrophy. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e001893.	1.6	40
118	Prevalence of malignant arrhythmia and sudden cardiac death in takotsubo syndrome and its management. <i>Europace</i> , 2018, 20, 843-850.	0.7	61
119	Psychiatric Disease Among Patients With Takotsubo Syndrome. <i>Psychosomatics</i> , 2018, 59, 101-102.	2.5	1
120	Bedside implantation of a new temporary vena cava inferior filter - Safety and efficacy results of the European ANGEL-Registry. <i>Journal of Critical Care</i> , 2018, 44, 39-44.	1.0	5
121	Atrial fibrillation impacts the outcome in Takotsubo syndrome. <i>International Journal of Cardiology</i> , 2018, 251, 57.	0.8	1
122	P3818 Kinetic changes in a mutant hERG channel (N588K) in human-induced pluripotent stem cell-derived cardiomyocytes. <i>European Heart Journal</i> , 2018, 39, .	1.0	0
123	P3821 Lipopolysaccharides inhibited T-type calcium channels in human-induced pluripotent stem cell-derived cardiomyocytes. <i>European Heart Journal</i> , 2018, 39, .	1.0	0
124	P2870 Nucleoside diphosphate kinase B increases the pacemaker activity in human induced pluripotent stem cell-derived cardiomyocytes. <i>European Heart Journal</i> , 2018, 39, .	1.0	0
125	P2866 Drug-testing using human-induced pluripotent stem cell-derived cardiomyocytes from a patient with short QT syndrome. <i>European Heart Journal</i> , 2018, 39, .	1.0	0
126	COPD increases cardiac mortality in patients presenting with ventricular tachyarrhythmias and aborted cardiac arrest. <i>Respiratory Medicine</i> , 2018, 145, 153-160.	1.3	5

#	ARTICLE	IF	CITATIONS
127	Long-Term Follow-Up of Patients With Short QT Syndrome: Clinical Profile and Outcome. <i>Journal of the American Heart Association</i> , 2018, 7, e010073.	1.6	35
128	Cognitive Deficit in Heart Failure Patients. <i>JACC: Heart Failure</i> , 2018, 6, 888-889.	1.9	0
129	Short-term and long-term incidence of stroke in Takotsubo syndrome. <i>ESC Heart Failure</i> , 2018, 5, 1191-1194.	1.4	8
130	Letter by El-Batrawy et al Regarding Article, "Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA ₂ DS ₂ -VASc-VA Score Rather Than CHA ₂ DS ₂ -VASc?" <i>Circulation</i> , 2018, 138, 441-442.	1.6	0
131	Reduced Na ⁺ Current in Native Cardiomyocytes of a Brugada Syndrome Patient Associated With β -2-Syntrophin Mutation. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002263.	1.6	11
132	P3822 Esophageal cancer related gene-4 affects multiple ion channel expression in human-induced stem cell-derived cardiomyocytes. <i>European Heart Journal</i> , 2018, 39, .	1.0	2
133	Type 2 diabetes is independently associated with all-cause mortality secondary to ventricular tachyarrhythmias. <i>Cardiovascular Diabetology</i> , 2018, 17, 125.	2.7	27
134	Sleep apnea as an attributable risk for atrial fibrillation. <i>International Journal of Cardiology</i> , 2018, 264, 103.	0.8	0
135	The pathophysiology of arrhythmias in arrhythmogenic right ventricular cardiomyopathy. <i>Europace</i> , 2018, 20, f138-f138.	0.7	1
136	Ion Channel Expression and Characterization in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Stem Cells International</i> , 2018, 2018, 1-14.	1.2	60
137	Response to Comment on Stiermaier et al. Prevalence and Prognostic Impact of Diabetes in Takotsubo Syndrome: Insights From the International, Multicenter GEIST Registry. <i>Diabetes Care</i> 2018;41:1084-1088. <i>Diabetes Care</i> , 2018, 41, e122-e122.	4.3	2
138	Reponse to Qi et al. regarding the letter to the Editor "Development of Takotsubo syndrome and cancer may share a common signaling pathway" <i>International Journal of Cardiology</i> , 2018, 270, 79.	0.8	0
139	Galectin-3 Reflects the Echocardiographic Grades of Left Ventricular Diastolic Dysfunction. <i>Annals of Laboratory Medicine</i> , 2018, 38, 306-315.	1.2	22
140	Beta-Blockers and ACE Inhibitors Are Associated with Improved Survival Secondary to Ventricular Tachyarrhythmia. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 353-363.	1.3	16
141	Clinical outcomes associated with catecholamine use in patients diagnosed with Takotsubo cardiomyopathy. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 54.	0.7	35
142	Letter by El-Batrawy et al Regarding Article, "Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe)" <i>Circulation</i> , 2018, 137, 2083-2084.	1.6	0
143	Long-Term Prognosis of Patients With Takotsubo Syndrome. <i>Journal of the American College of Cardiology</i> , 2018, 72, 874-882.	1.2	224
144	Cardiac voltage-sodium channel mutations association with primary electrical diseases. <i>Europace</i> , 2018, 20, 1707-1707.	0.7	1

#	ARTICLE	IF	CITATIONS
145	The link between atrial fibrillation and hereditary channelopathies. <i>Europace</i> , 2018, 20, 1872-1872.	0.7	6
146	Reply to: Diabetes mellitus and Takotsubo syndrome: Dissecting the paradox. <i>International Journal of Cardiology</i> , 2017, 229, 135.	0.8	1
147	Letter by El-Batrawy et al Regarding Article, "Takotsubo-Like Myocardial Dysfunction in Ischemic Stroke: A Hospital-Based Registry and Systematic Literature Review". <i>Stroke</i> , 2017, 48, e72.	1.0	1
148	Prevalence of cancer in Takotsubo cardiomyopathy: Short and long-term outcome. <i>International Journal of Cardiology</i> , 2017, 238, 159-165.	0.8	62
149	Catecholamine in takotsubo syndrome. <i>International Journal of Cardiology</i> , 2017, 233, 97.	0.8	4
150	Procedural success and intra-hospital outcome related to left atrial appendage morphology in patients that receive an interventional left atrial appendage closure. <i>Clinical Cardiology</i> , 2017, 40, 566-574.	0.7	10
151	Impact of stress on Takotsubo syndrome. <i>International Journal of Cardiology</i> , 2017, 242, 33.	0.8	0
152	Dissecting the diagnosis of biventricular myocarditis. <i>International Journal of Cardiology</i> , 2017, 242, 43.	0.8	0
153	Impact and management of left ventricular function on the prognosis of Takotsubo syndrome. <i>European Journal of Clinical Investigation</i> , 2017, 47, 477-485.	1.7	14
154	Clinical outcomes of femoral closure compared to radial compression devices following percutaneous coronary intervention: the FERARI study. <i>Heart and Vessels</i> , 2017, 32, 520-530.	0.5	4
155	Hormone Status Correlates With Incidence of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2312-2313.	1.2	3
156	Occlusion of left atrial appendage affects metabolomic profile: focus on glycolysis, tricarboxylic acid and urea metabolism. <i>Metabolomics</i> , 2017, 13, 127.	1.4	10
157	Letter by El-Batrawy et al Regarding Article, "The Brugada Syndrome Susceptibility Gene HEY2 Modulates Cardiac Transmural Ion Channel Patterning and Electrical Heterogeneity". <i>Circulation Research</i> , 2017, 121, e20.	2.0	2
158	β-Blockers and Outcome After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1685.	1.2	1
159	Atrial fibrillation as a risk factor for worse outcome in acute coronary syndrome. <i>International Journal of Cardiology</i> , 2017, 246, 53.	0.8	3
160	Reply to "Cancer and Takotsubo Cardiomyopathy: More questions than answers". <i>International Journal of Cardiology</i> , 2017, 242, 14.	0.8	0
161	Incidence and Prognostic Relevance of Cardiopulmonary Failure in Takotsubo Cardiomyopathy. <i>Scientific Reports</i> , 2017, 7, 14673.	1.6	9
162	Lipopolysaccharides induced inflammatory responses and electrophysiological dysfunctions in human-induced pluripotent stem cell derived cardiomyocytes. <i>Scientific Reports</i> , 2017, 7, 2935.	1.6	111

#	ARTICLE	IF	CITATIONS
163	Impact of concomitant atrial fibrillation on the prognosis of Takotsubo cardiomyopathy. <i>Europace</i> , 2017, 19, 1288-1292.	0.7	54
164	Ezetimibe inhibits platelet activation and uPAR expression on endothelial cells. <i>International Journal of Cardiology</i> , 2017, 227, 858-862.	0.8	16
165	Ballooning Pattern and Related Outcome in Takotsubo Syndrome. <i>American Journal of Cardiology</i> , 2017, 120, e63.	0.7	0
166	Endothelial dysfunction in takotsubo syndrome. <i>International Journal of Cardiology</i> , 2017, 234, 101.	0.8	3
167	Predictors of mortality in Takotsubo cardiomyopathy. <i>European Journal of Heart Failure</i> , 2017, 19, 158-158.	2.9	7
168	Comparison and Outcome Analysis of Patients with Takotsubo Cardiomyopathy Triggered by Emotional Stress or Physical Stress. <i>Frontiers in Psychology</i> , 2017, 8, 527.	1.1	21
169	Coincidental coronary artery disease impairs outcome in patients with takotsubo cardiomyopathy. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2017, 110, 483-488.	0.2	16
170	Biomarkers in Cardiomyopathies and Prediction of Sudden Cardiac Death. <i>Current Pharmaceutical Biotechnology</i> , 2017, 18, 472-481.	0.9	15
171	Age related differences and outcome of patients with Takotsubo syndrome. <i>Journal of Geriatric Cardiology</i> , 2017, 14, 632-638.	0.2	6
172	Prevalence, Clinical Characteristics, and Predictors of Patients with Thromboembolic Events in Takotsubo Cardiomyopathy. <i>Clinical Medicine Insights: Cardiology</i> , 2016, 10, CMC.S38151.	0.6	35
173	Solid Right Ventricular Compression by Intraventricular Septum-Hematoma Induced after Percutaneous Coronary Intervention. <i>Case Reports in Cardiology</i> , 2016, 2016, 1-4.	0.1	3
174	Hyperthermia Influences the Effects of Sodium Channel Blocking Drugs in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>PLoS ONE</i> , 2016, 11, e0166143.	1.1	28
175	Left atrial appendage morphology, echocardiographic characterization, procedural data and in-hospital outcome of patients receiving left atrial appendage occlusion device implantation: a prospective observational study. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 25.	0.7	12
176	Takotsubo Syndrome and Embolic Events. <i>Heart Failure Clinics</i> , 2016, 12, 543-550.	1.0	36
177	Association of a congenital long QT syndrome type 1 with Takotsubo cardiomyopathy. <i>Clinical Case Reports (discontinued)</i> , 2016, 4, 789-792.	0.2	3
178	Characteristics and long-term outcome of right ventricular involvement in Takotsubo cardiomyopathy. <i>International Journal of Cardiology</i> , 2016, 220, 371-375.	0.8	40
179	- LAA Occluder View for post-implantation Evaluation (LOVE) - standardized imaging proposal evaluating implanted left atrial appendage occlusion devices by cardiac computed tomography. <i>BMC Medical Imaging</i> , 2016, 16, 25.	1.4	29
180	Comparison and outcome analysis of patients with apical and non-apical takotsubo cardiomyopathy. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 109, 797-802.	0.2	18

#	ARTICLE	IF	CITATIONS
181	Biomarker evaluation as a potential cause of gender differences in obesity paradox among patients with STEMI. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 88-94.	0.3	6
182	Triple head-to-head comparison of fibrotic biomarkers galectin-3, osteopontin and gremlin-1 for long-term prognosis in suspected and proven acute heart failure patients. <i>International Journal of Cardiology</i> , 2016, 203, 398-406.	0.8	13
183	Clinical and echocardiographic analysis of patients suffering from recurrent takotsubo cardiomyopathy. <i>Journal of Geriatric Cardiology</i> , 2016, 13, 888-893.	0.2	21
184	Expression of Inflammation-related Intercellular Adhesion Molecules in Cardiomyocytes In Vitro and Modulation by Pro-inflammatory Agents. <i>In Vivo</i> , 2016, 30, 213-7.	0.6	1
185	Design and Rationale of the Femoral Closure versus Radial Compression Devices Related to Percutaneous Coronary Interventions (FERARI) Study. <i>Clinical Medicine Insights: Cardiology</i> , 2015, 9, CMC.S31932.	0.6	5
186	New Oral Anticoagulation after Heart Valve Replacement. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2015, 15, 106-109.	0.2	1